/GPCR

GPCR Stock - Structure Therapeutics Inc.

Q: What is the analyst price target for GPCR?

Analyst price target information is not currently available for GPCR.

Q: What is GPCR's market cap?

Market capitalization information is not currently available for GPCR.

Healthcare|Biotechnology|NASDAQ

$77.92+12.34%

+$8.56 (+12.34%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+15.5%upside

Target: $90.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for GPCR

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-2.15

52W High$94.90

52W Low$13.22

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	$-20,034
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-158,228,000	$-102,775,000	$-52,561,000	$-37,696,000	$-15,933,378
Net Income	$-122,526,000	$-89,620,000	$-51,321,000	$-40,008,000	$-15,903,326
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-2.34	$-2.43	$-1.44	$-1.20	$-0.45

Company Overview

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Visit Website

Earnings History & Surprises

GPCR

Beat Rate

42%

Last 12 quarters

Avg Surprise

-18.5%

EPS vs Estimate

Beats / Misses

5/7

Last 12 quarters

Latest EPS

$-0.37

Q4 2025

EPS Surprise History

Q1 24

+19.0%

$-0.17vs$-0.21

Q2 24

+9.5%

$-0.19vs$-0.21

Q3 24

+21.7%

$-0.18vs$-0.23

Q4 24

-5.3%

$-0.20vs$-0.19

Q1 25

+4.3%

$-0.22vs$-0.23

Q2 25

-12.5%

$-0.27vs$-0.24

Q3 25

-28.6%

$-0.36vs$-0.28

Q4 25

-2.8%

$-0.37vs$-0.36

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 6, 2026	—	—	—	—
Q1 2026	Feb 26, 2026	$-0.35	—	—	—
Q4 2025	Nov 6, 2025	$-0.36	$-0.37	-2.8%	✗ MISS
Q3 2025	Aug 6, 2025	$-0.28	$-0.36	-28.6%	✗ MISS
Q2 2025	May 8, 2025	$-0.24	$-0.27	-12.5%	✗ MISS
Q1 2025	Feb 27, 2025	$-0.23	$-0.22	+4.3%	✓ BEAT
Q4 2024	Nov 13, 2024	$-0.19	$-0.20	-5.3%	✗ MISS
Q3 2024	Aug 8, 2024	$-0.23	$-0.18	+21.7%	✓ BEAT
Q2 2024	May 9, 2024	$-0.21	$-0.19	+9.5%	✓ BEAT
Q1 2024	Mar 8, 2024	$-0.21	$-0.17	+19.0%	✓ BEAT
Q4 2023	Nov 14, 2023	$-0.29	$-0.62	-113.8%	✗ MISS
Q3 2023	Aug 10, 2023	$-0.28	$-0.60	-114.3%	✗ MISS
Q2 2023	May 11, 2023	$-0.41	$-0.25	+39.0%	✓ BEAT
Q1 2023	Mar 31, 2023	$-0.82	$-1.14	-39.0%	✗ MISS
Q3 2022	Sep 30, 2022	—	$-0.12	—	—
Q2 2022	Jun 30, 2022	—	$-0.13	—	—
Q1 2022	Mar 31, 2022	—	$-0.12	—	—
Q4 2021	Dec 31, 2021	—	$-0.00	—	—

Frequently Asked Questions about GPCR

What is GPCR's current stock price?

Structure Therapeutics Inc. (GPCR) is currently trading at $77.92 per share. The stock has moved +12.34% today.

What is the analyst price target for GPCR?

The average analyst price target for GPCR is $90.00, based on 1 analyst.

What sector is Structure Therapeutics Inc. in?

Structure Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is GPCR's market cap?

Structure Therapeutics Inc. has a market capitalization of $4.49 billion, making it a mid-cap company.

Does GPCR pay dividends?

No, Structure Therapeutics Inc. does not currently pay a dividend to shareholders.